<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Ophthalmology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/ophthalmology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Uveitis incidence increases following herpes zoster</title>
		<link>http://www.thedoctorschannel.com/view/uveitis-incidence-increases-following-herpes-zoster/</link>
		<pubDate>Thu, 12 Apr 2012 22:44:45 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[herpes zoster]]></category>
		<category><![CDATA[uveitis]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28025</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – An episode of herpes zoster is associated with an increased risk of developing anterior uveitis in the following year, according to the results of a Taiwanese epidemiological study reported in the April issue of the Archives of Ophthalmology. “We suggest that patient eye condition be evaluated following diagnosis with HZ -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Uveitis incidence increases following herpes zoster]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – An episode of herpes zoster is associated with an increased risk of developing anterior uveitis in the following year, according to the results of a Taiwanese epidemiological study reported in the April issue of the Archives of Ophthalmology. “We suggest that patient eye condition be evaluated following diagnosis with HZ -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/uveitis-incidence-increases-following-herpes-zoster/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120412epid006.jpg"/>
	<media:keywords><![CDATA[herpes zoster,uveitis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Bevacizumab efficacy in diabetic macular edema sustained at 2 years</title>
		<link>http://www.thedoctorschannel.com/view/bevacizumab-efficacy-in-diabetic-macular-edema-sustained-at-2-years/</link>
		<pubDate>Wed, 11 Apr 2012 22:02:46 +0000</pubDate> 
				<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Bevacizumab]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[macular edema]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27975</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A study conducted at Moorfields Eye Hospital in London, UK, finds that the benefits seen at 1 year with bevacizumab treatment of macular edema are sustained at 2 years, with comparatively few intravitreal injections. “This finding will be reassuring to physicians charged with delivery of this relatively new treatment,&#8221; conclude -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[Bevacizumab efficacy in diabetic macular edema sustained at 2 years]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A study conducted at Moorfields Eye Hospital in London, UK, finds that the benefits seen at 1 year with bevacizumab treatment of macular edema are sustained at 2 years, with comparatively few intravitreal injections. “This finding will be reassuring to physicians charged with delivery of this relatively new treatment,&#8221; conclude -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/bevacizumab-efficacy-in-diabetic-macular-edema-sustained-at-2-years/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120411drgd006.jpg"/>
	<media:keywords><![CDATA[Bevacizumab,diabetes,macular edema]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Oral bisphosphonates linked to ocular side effects</title>
		<link>http://www.thedoctorschannel.com/view/oral-bisphosphonates-linked-to-ocular-side-effects/</link>
		<pubDate>Wed, 04 Apr 2012 22:06:07 +0000</pubDate> 
				<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[bisphosphonates]]></category>
		<category><![CDATA[scleritis]]></category>
		<category><![CDATA[uveitis]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27636</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist,” conclude the authors of the report in the Canadian -]]></description>
		
			<media:content duration="1:17" medium="video">
		<media:title><![CDATA[Oral bisphosphonates linked to ocular side effects]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist,” conclude the authors of the report in the Canadian -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/oral-bisphosphonates-linked-to-ocular-side-effects/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120404clin003.jpg"/>
	<media:keywords><![CDATA[bisphosphonates,scleritis,uveitis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Verteporfin does not improve efficacy of ranibizumab for macular degeneration</title>
		<link>http://www.thedoctorschannel.com/view/verteporfin-does-not-improve-efficacy-of-ranibizumab-for-macular-degeneration/</link>
		<pubDate>Mon, 02 Apr 2012 22:29:28 +0000</pubDate> 
				<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[DENALI]]></category>
		<category><![CDATA[macular degeneration]]></category>
		<category><![CDATA[MONT BLANC]]></category>
		<category><![CDATA[ranibizumab]]></category>
		<category><![CDATA[Verteporfin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27567</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Results of two trials indicate that verteporfin photodynamic therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). The findings are reported in two papers in Ophthalmology online March 19, covering 12-month outcomes in the MONT BLANC trial conducted -]]></description>
		
			<media:content duration="1:55" medium="video">
		<media:title><![CDATA[Verteporfin does not improve efficacy of ranibizumab for macular degeneration]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Results of two trials indicate that verteporfin photodynamic therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). The findings are reported in two papers in Ophthalmology online March 19, covering 12-month outcomes in the MONT BLANC trial conducted -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/verteporfin-does-not-improve-efficacy-of-ranibizumab-for-macular-degeneration/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120402drgd003.jpg"/>
	<media:keywords><![CDATA[DENALI,macular degeneration,MONT BLANC,ranibizumab,Verteporfin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Topical or regional anesthesia for cataract surgery?</title>
		<link>http://www.thedoctorschannel.com/view/topical-or-regional-anesthesia-for-cataract-surgery/</link>
		<pubDate>Thu, 08 Mar 2012 08:10:56 +0000</pubDate> 
				<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[anesthesia]]></category>
		<category><![CDATA[cataract surgery]]></category>
		<category><![CDATA[peribulbar]]></category>
		<category><![CDATA[phacoemulsification]]></category>
		<category><![CDATA[retrobulbar]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=26159</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In patients undergoing cataract surgery, topical anesthesia doesn’t provide the same degree of pain relief as regional anesthesia although it’s associated with fewer complications and patients seem to prefer it, a meta-analytic review of relevant research suggests. Phacoemulsification with intraocular lens implantation is the current standard of care procedure for -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[Topical or regional anesthesia for cataract surgery?]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In patients undergoing cataract surgery, topical anesthesia doesn’t provide the same degree of pain relief as regional anesthesia although it’s associated with fewer complications and patients seem to prefer it, a meta-analytic review of relevant research suggests. Phacoemulsification with intraocular lens implantation is the current standard of care procedure for -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/topical-or-regional-anesthesia-for-cataract-surgery/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120308clin011.jpg"/>
	<media:keywords><![CDATA[anesthesia,cataract surgery,peribulbar,phacoemulsification,retrobulbar]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Postcataract surgery endophthalmitis rates declining in United States</title>
		<link>http://www.thedoctorschannel.com/view/postcataract-surgery-endophthalmitis-rates-declining-in-united-states/</link>
		<pubDate>Wed, 22 Feb 2012 22:27:15 +0000</pubDate> 
				<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[cataract]]></category>
		<category><![CDATA[cataracts]]></category>
		<category><![CDATA[endophthalmitis]]></category>
		<category><![CDATA[ophthalmology]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=25340</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Postcataract surgery endophthalmitis rates in the United States declined slightly between 2003 and 2004, but there is still room for improvement, according to a report in the January 31st online Ophthalmology. “Endophthalmitis rates in the US in 2003-2004 were lower than in previous years; however, they were still higher than -]]></description>
		
			<media:content duration="01:36" medium="video">
		<media:title><![CDATA[Postcataract surgery endophthalmitis rates declining in United States]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Postcataract surgery endophthalmitis rates in the United States declined slightly between 2003 and 2004, but there is still room for improvement, according to a report in the January 31st online Ophthalmology. “Endophthalmitis rates in the US in 2003-2004 were lower than in previous years; however, they were still higher than -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/postcataract-surgery-endophthalmitis-rates-declining-in-united-states/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/02/Thumbnail_20120222epid002.jpg"/>
	<media:keywords><![CDATA[cataract,cataracts,endophthalmitis,ophthalmology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Vitamin A improves retinal sensitivity in premature infants</title>
		<link>http://www.thedoctorschannel.com/view/vitamin-a-improves-retinal-sensitivity-in-premature-infants/</link>
		<pubDate>Mon, 20 Feb 2012 23:27:47 +0000</pubDate> 
				<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[preemie]]></category>
		<category><![CDATA[preemies]]></category>
		<category><![CDATA[premature]]></category>
		<category><![CDATA[retina]]></category>
		<category><![CDATA[retinopathy]]></category>
		<category><![CDATA[retinopathy of prematurity]]></category>
		<category><![CDATA[retinopathy prematurity]]></category>
		<category><![CDATA[ROP]]></category>
		<category><![CDATA[Vitamin A]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=25137</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For preterm neonates at risk of retinopathy, high-dose vitamin A supplementation started soon after birth produces a significant increase in retinal function, a Scottish group reports in the Journal of Pediatrics online January 30th. “This study indicates that the beneficial effects of early vitamin A supplementation for preterm infants extend -]]></description>
		
			<media:content duration="01:31" medium="video">
		<media:title><![CDATA[Vitamin A improves retinal sensitivity in premature infants]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For preterm neonates at risk of retinopathy, high-dose vitamin A supplementation started soon after birth produces a significant increase in retinal function, a Scottish group reports in the Journal of Pediatrics online January 30th. “This study indicates that the beneficial effects of early vitamin A supplementation for preterm infants extend -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/vitamin-a-improves-retinal-sensitivity-in-premature-infants/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/02/Thumbnail_20120220clin002.jpg"/>
	<media:keywords><![CDATA[preemie,preemies,premature,retina,retinopathy,retinopathy of prematurity,retinopathy prematurity,ROP,Vitamin A]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Longer screening interval for retinopathy might be safe for some diabetics</title>
		<link>http://www.thedoctorschannel.com/view/longer-screening-interval-for-retinopathy-might-be-safe-for-some-diabetics/</link>
		<pubDate>Tue, 07 Feb 2012 00:06:32 +0000</pubDate> 
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[maculopathy]]></category>
		<category><![CDATA[retinopathy]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=24492</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Patients with type 2 diabetes who don’t have retinopathy at baseline have a relatively low risk of developing eye complications during 5 to 10 years of follow-up, according to a population-based UK study. “Screening intervals longer than a year may be appropriate for such patients,” suggest the authors of the -]]></description>
		
			<media:content duration="1:37" medium="video">
		<media:title><![CDATA[Longer screening interval for retinopathy might be safe for some diabetics]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Patients with type 2 diabetes who don’t have retinopathy at baseline have a relatively low risk of developing eye complications during 5 to 10 years of follow-up, according to a population-based UK study. “Screening intervals longer than a year may be appropriate for such patients,” suggest the authors of the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/longer-screening-interval-for-retinopathy-might-be-safe-for-some-diabetics/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/02/Longer-screening-interval-for-retinopathy-might-be-safe-for-some-diabetics.jpg"/>
	<media:keywords><![CDATA[diabetes,maculopathy,retinopathy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Oral azithromycin superior to topical tetracycline after trichiasis surgery</title>
		<link>http://www.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/</link>
		<pubDate>Thu, 15 Dec 2011 20:47:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[azithromycin]]></category>
		<category><![CDATA[ophthalmology]]></category>
		<category><![CDATA[surgery]]></category>
		<category><![CDATA[topical tetracycline]]></category>
		<category><![CDATA[Trichiasis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A single dose of oral azithromycin reduces the recurrence of trichiasis for up to three years more so than a six-week regimen of topical tetracycline, researchers report. This strategy “fits” with the World Health Organization&#8217;s multifaceted strategy for eliminating trachoma by 2020, Dr. Sheila West, of the Dana Center for -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[Oral azithromycin superior to topical tetracycline after trichiasis surgery]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A single dose of oral azithromycin reduces the recurrence of trichiasis for up to three years more so than a six-week regimen of topical tetracycline, researchers report. This strategy “fits” with the World Health Organization&#8217;s multifaceted strategy for eliminating trachoma by 2020, Dr. Sheila West, of the Dana Center for -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/oral-azithromycin-superior-to-topical-tetracycline-after-trichiasis-surgery-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4935.jpg"/>
	<media:keywords><![CDATA[azithromycin,ophthalmology,surgery,topical tetracycline,Trichiasis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Nail bed hemorrhage associated with optic disc hemorrhage in glaucoma</title>
		<link>http://www.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/</link>
		<pubDate>Wed, 02 Nov 2011 22:31:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[disc hemorrhage]]></category>
		<category><![CDATA[nail bed hemorrhage]]></category>
		<category><![CDATA[retinal nerve fiber]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Nail bed hemorrhage may serve as a clinical marker of optic disc hemorrhage in patients with glaucoma, researchers from South Korea report in the October Archives of Ophthalmology. Nailfold capillaroscopy is a simple, safe, noninvasive, and inexpensive technique for studying the microcirculation in vivo. In ophthalmology, it has been used -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Nail bed hemorrhage associated with optic disc hemorrhage in glaucoma]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Nail bed hemorrhage may serve as a clinical marker of optic disc hemorrhage in patients with glaucoma, researchers from South Korea report in the October Archives of Ophthalmology. Nailfold capillaroscopy is a simple, safe, noninvasive, and inexpensive technique for studying the microcirculation in vivo. In ophthalmology, it has been used -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/nail-bed-hemorrhage-associated-with-optic-disc-hemorrhage-in-glaucoma/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4799.jpg"/>
	<media:keywords><![CDATA[disc hemorrhage,nail bed hemorrhage,retinal nerve fiber]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
